Hur Gyu-Young, Lee Ji-Ho, Park Hae-Sim
aDepartment of Internal Medicine, Korea University College of Medicine, Seoul bDepartment of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.
Curr Opin Allergy Clin Immunol. 2017 Aug;17(4):304-308. doi: 10.1097/ACI.0000000000000370.
Respiratory allergies, including asthma and allergic rhinitis can also occur in the elderly. Allergen immunotherapy for allergic diseases is the only disease-modifying treatment for patients with allergies available thus far. Here, we review current evidence supporting the use of allergen immunotherapy in the elderly and discuss its efficacy and utility for the treatment of respiratory allergic diseases in this setting.
Subcutaneous and/or sublingual immunotherapy are effective therapeutic options in not only young but also older patients. Allergen immunotherapy reduces medication and symptom scores in the elderly and can thus be safely prescribed in this population.
Elderly individuals with proven, clinically relevant immunoglobulin E sensitization to inhalant allergens may benefit from allergen immunotherapy for respiratory allergic diseases. Older patients without contraindications should therefore be considered for treatment, with the additional benefit of reduced medication and symptom scores.
呼吸道过敏，包括哮喘和过敏性鼻炎，在老年人中也可能发生。变应原免疫疗法是目前唯一可用于治疗过敏性疾病患者的疾病改善疗法。在此，我们综述支持在老年人中使用变应原免疫疗法的现有证据，并讨论其在这种情况下治疗呼吸道过敏性疾病的疗效和实用性。
皮下和/或舌下免疫疗法不仅对年轻患者，而且对老年患者都是有效的治疗选择。变应原免疫疗法可降低老年人的药物使用量和症状评分，因此可以在该人群中安全地开具处方。
经证实对吸入性变应原具有临床相关免疫球蛋白E致敏的老年人，可能从呼吸道过敏性疾病的变应原免疫疗法中获益。因此，对于没有禁忌证的老年患者应考虑进行治疗，其额外益处是降低药物使用量和症状评分。
